XIENCE V Everolimus Eluting Coronary Stent System India Post-marketing Single-Arm Study.
Phase of Trial: Phase IV
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms XIENCE-V-India
- Sponsors Abbott Laboratories
- 24 Aug 2016 Last checked against Clinical Trials Registry - India.
- 13 Aug 2012 Actual end date (Aug 2012) added as reported by ClinicalTrials.gov.
- 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.